摘要
Treatment of multiple myeloma(MM)has advanced dramatically in the past two decades.However,under the conditions of the COVID-19 pandemic,treatment strategies have been modified accordingly.Numerous novel agents,updated trials,and major advances in myeloma have been reported in the American Society of Hematology 2020 annual meeting,either for transplant-eligible or ineligible patients.Hot topics such as the significance of autologous stem cell transplantation(ASCT),development of novel agents,and chimeric antigen receptor-T(CAR-T)cells have been widely discussed.The triplet regimen bortezomib,lenalidomide,and dexamethasone(VRd)is recommended as the standard first-line treatment,and the addition of a fourth drug improves efficacy and survival.The value of ASCT remains undoubtful,even in the era of quadruplet induction.Dual-drug maintenance,including proteasome inhibitors and immunomodulatory drugs,overcomes unfavorable outcomes in high-risk patients.For relapsed/refractory myeloma(RRMM)patients,novel agents such as selinexor and venetoclax are superior.CAR-T cells and other cell-surface-targeted therapies also appear promising.
